Join the 'Hyperphosphatemia of Renal Failure' group to help and get support from people like you.

Hyperphosphatemia of Renal Failure Blog

Keryx Biopharmaceuticals Announces Trade Name Auryxia for Ferric Citrate

Posted 9 days ago by Drugs.com

NEW YORK, Nov. 17, 2014 (GLOBE NEWSWIRE) – Keryx Biopharmaceuticals, Inc., a biopharmaceutical company focused on bringing innovative therapies to market for patients with renal disease, today announced that the U.S. Food and Drug Administration (FDA) has approved the trade name Auryxia (ferric citrate) for its FDA-approved ferric citrate. Auryxia, an iron-based phosphate binder, was approved by the FDA to control serum phosphorus levels in patients with chronic kidney disease (CKD) on dialysis in September 2014. Ron Bentsur, Chief Executive Officer of Keryx, commented, "We are excited to receive FDA approval of the trade name Auryxia. We look forward to launching Auryxia in the U.S. at year end and to providing nephrologists with an effective phosphate binder for dialysis-dependent CKD patients." For more information about Auryxia, please visit www.Auryxia.com. About End Stage ... Read more

Related support groups: Ferric Citrate, Hyperphosphatemia of Renal Failure

Velphoro Receives US FDA Approval for the Treatment of Hyperphosphatemia in Chronic Kidney Disease Patients on Dialysis

Posted 3 Dec 2013 by Drugs.com

November 28, 2013, Velphoro (sucroferric oxyhydroxide) has received US Food and Drug Administration (FDA) approval for the control of serum phosphorus levels in patients with Chronic Kidney Disease (CKD) on dialysis. Velphoro will be launched in the US by Fresenius Medical Care North America in 2014. Velphoro (previously known as PA21) is an iron-based, calcium-free, chewable phosphate binder. US approval was based on a pivotal Phase III study, which met its primary and secondary endpoints. The study demonstrated that Velphoro successfully controls hyperphosphatemia with fewer pills than sevelamer carbonate, the current standard of care in patients with CKD on dialysis1. The average daily dose to control hyperphosphatemia was 3.3 pills per day after 52 weeks. Velphoro was developed by Vifor Pharma. In 2011, all rights were transferred to Vifor Fresenius Medical Care Renal Pharma, a ... Read more

Related support groups: Hyperphosphatemia of Renal Failure

For Dialysis Patients, More Pills = Lower Quality of Life

Posted 13 May 2009 by Drugs.com

WEDNESDAY, May 13 – The more pills that kidney dialysis patients take, the more side effects they suffer and the worse their quality of life, a new study finds. Dialysis patients have to take more pills than most patients with other chronic diseases. In this study, researchers at the Los Angeles Biomedical Research Institute looked at the "pill burden" in 233 dialysis patients in the United States. The patients took an average of 19 pills a day, but 25 percent took more than 25 pills a day. Patients with a high pill burden reported poorer physical health. Phosphate binders, medications that control the level of phosphorous in the blood, accounted for about half of the daily pill burden. The study found that 62 percent of patients didn't take these medications as directed. The more phosphate binders patients were prescribed, the less likely they were to take the medications as directed, ... Read more

Related support groups: Hyperphosphatemia of Renal Failure

Ask a Question

Further Information

Related Condition Support Groups

Renal Failure

Related Drug Support Groups

Carafate, sucralfate, Renvela, Renagel, magnesium carbonate, Fosrenol, sevelamer, MagneBind 200, Velphoro, view more... Marblen, MagneBind 300, calcium carbonate / magnesium carbonate, sucroferric oxyhydroxide, ferric citrate, lanthanum carbonate, Mag-Carb, Dewees Carminative